Expertise in
9
conditions

Dr. Josh D. Simmons

Hematology
Archbold Cancer Center
919 S Broad St, 
Thomasville, GA 
Accepting New Patients
18 Years of Experience
Expertise in
9
conditions
Archbold Cancer Center
919 S Broad St, 
Thomasville, GA 

Overview

Josh Simmons is a Hematologist practicing medicine in Thomasville, Georgia. He has been practicing medicine for over 18 years.

Dr. Simmons is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Follicular Lymphoma, Hemangioma Thrombocytopenia Syndrome, Immune Thrombocytopenic Purpura (ITP), and Thrombectomy.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 14 clinical trials. Dr. Simmons is currently accepting new patients.

Graduate Year

2008

Specialties

Hematology

Licenses

Internal Medicine in GA

Hospital Affiliations

Grady General Hospital
Memorial Hospital And Manor
Archbold Memorial Hospital
Archbold Mitchell

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Archbold Cancer Center
919 S Broad St, Thomasville, GA 31792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

4 Total Publications

Drivers of Professional Satisfaction in Emergency Medicine Residency Training in the US.
Drivers of Professional Satisfaction in Emergency Medicine Residency Training in the US.
Journal: AEM education and training
Published: April 23, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Betty S. Pace
Hematology | Oncology
Expertise in
8
conditions
Dr. Betty S. Pace
Hematology | Oncology
Referral may be required

Phoebe Putney Memorial Hospital

417 W 3rd Ave, 
Albany, GA 
 (53.8 miles away)
229-312-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Betty Pace is a Hematologist and an Oncologist practicing medicine in Albany, Georgia. Dr. Pace is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Pace is currently accepting new patients.

Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Expertise in
39
conditions
Dr. Scott M. Bradfield
Hematology | Oncology
Referral may be required

Nemours Children's Health, Tallahassee

2418 E. Plaza Drive, 
Tallahassee, FL 
 (30.1 miles away)
904-697-3600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

"I’m a pediatric oncologist (cancer specialist) based at the Nemours Children’s Specialty Care, Jacksonville. I’m a triathlete, married with three children, with an interest in finding ways to constantly improve cancer care for children. We returned to Florida, my home state, after travelling the country to complete my medical training. While I was growing up, my mother worked in an OB/GYN office, so I always said I wanted to do the same """"because I love to work with kids."""" At that time, nobody explained to me that OB/GYNs treat women and it’s really pediatricians who treat kids. By medical school, it was clear pediatrics was what I was interested in. I love the personal interactions with families during some of their happiest and also most difficult times. I find the clinical aspects and science behind oncology fascinating. I specialize in cancer care for children and try to find ways to improve the care they receive. I am currently leading the expansion of our treatment protocols for relapsed disease so patients can have more aggressive options if their cancer returns.". Dr. Bradfield is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Bradfield is board certified in American Board Of Pediatrics. Dr. Bradfield is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

South Georgia Medical Center

2501 N Patterson St, 
Valdosta, GA 
 (40.6 miles away)
229-259-4600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samuel Ofori is a Hematologist practicing medicine in Valdosta, Georgia. Dr. Ofori is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Anemia. Dr. Ofori is currently accepting new patients.

Frequently Asked Questions about Dr. Josh D. Simmons

How do I make an appointment with Dr. Josh D. Simmons?

You can book an appointment with Dr. Josh D. Simmons by calling their office at 800-852-2694. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Josh D. Simmons a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Josh D. Simmons is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Josh D. Simmons specialize in?

While Dr. Josh D. Simmons is a Hematology, they have specific expertise in Multiple Myeloma, Follicular Lymphoma, and Hemangioma Thrombocytopenia Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Josh D. Simmons participate in research or clinical trials?

Yes. Dr. Josh D. Simmons has published 4 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Josh D. Simmons's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Josh D. Simmons accept my insurance?

Dr. Josh D. Simmons accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 800-852-2694 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Simmons's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 45 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile